Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

Primary Objective: Evaluate the role of ctDNA positivity in decision making for postoperative therapy for non-small cell lung cancer. The plan for postoperative therapy will be declared after pathology report review and before the ctDNA result. We will assess if ctDNA result changed the planned therapy. Secondary Objectives: Evaluate personalized postoperative Chemo/ICPI/Targeted Therapies/Radiation Therapy in clearing ctDNA Evaluate the disease-free survival (DFS) and overall survival (OS) of stage II/III lung cancer patients with postoperative ctDNA positive status Exploratory Objective: Evaluate radiomics features based on serial CT thoracic CT scans to determine if radiomic features can be associated with ctDNA positivity/negativity.

NCT Number	NCT06979661
Lead Sponsor	Rutgers, The State University of New Jersey
Conditions	Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
Enrollment	25 participants
Start Date	2025-06-01
Primary Completion	2028-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-20